Mr. Rob Hill reports

EMERALD HEALTH THERAPEUTICS TO LEAD INTERNATIONAL AFFAIRS COUNCIL ON CBD AND HEMP'S DIALOG WITH FDA ON CBD PRODUCT POLICY AS PART OF THE AMERICAN TRADE ASSOCIATION FOR CANNABIS AND HEMP

Emerald Health Therapeutics Inc. has been appointed by the American Trade Association for Cannabis and Hemp (ATACH) to lead its international affairs council on cannabidiol and hemp in ATACH's engagement with the U.S. Food and Drug Administration (FDA) regarding policy pertaining to CBD-containing products and associated cross-border trade. The FDA is slated to begin public consultation on May 31 to discuss potential pathways for CBD products to come to market in the United States.

"Emerald Health Therapeutics is one of Canada's original licensed producers and has expertise on CBD extraction and associated regulatory development," said Michael Bronstein, president of ATACH. "We look forward to leveraging Emerald's knowledge and experience as we participate in the FDA process on how to best navigate and implement a potentially new regime for products containing cannabinoids in the United States."

"We are pleased to be asked to lead ATACH's international affairs council on CBD and Hemp," said Dr. Avtar Dhillon, president and executive chairman of Emerald. "We believe there is significant therapeutic and economic potential for CBD-related products generally and in the U.S., and we are eager to play a positive role in this policy formation process."

Allan Rewak, vice-president of communications and stakeholder relations of Emerald, has been appointed as the company's formal representative to ATACH and will utilize his experience in the Canadian cannabis legalization process to support the development of a reasonable and effective regulatory regime for CBD in the United States.

Emerald produces and sells its SYNC 25 CBD oil in the adult-use market and other high-CBD products in the medical market in Canada and has sourced hemp to produce allowable oils in the current Canadian legal framework. It is also employing advanced formulation and delivery technology with the goal to offer customers new product choices in conjunction with new Canadian legislation that is expected to allow a broader set of ingestible and topical products in the fall of 2019 and beyond.

About Emerald Health Therapeutics Inc.

Emerald Health Therapeutics is a Canadian licensed producer of cannabis. Its 50-per-cent-owned Pure Sunfarms joint venture in British Columbia is licensed and fully planted in the first of its two 1.1-million-square-foot greenhouses.

We seek Safe Harbor.